BioWorld

Sep. 29, 2006

FDA Clears Amgen's Vectibix, Adds To ImClone's Troubles

Late Wednesday, the FDA approved the next in a growing line of targeted cancer therapies, Amgen Inc.'s Vectibix (panitumumab). (BioWorld Today) Read More

Athenagen Series B Garners $50M For Alzheimer's, AMD

Grant Gives Alnylam $23M For Anti-Ebola Virus Work

Startup Alvine Aims At Celiac Disease, Closes $21M Round

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...